School Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
National Association of Diabetes Centres, Sydney, New South Wales Australia.
PLoS One. 2022 Feb 4;17(2):e0263511. doi: 10.1371/journal.pone.0263511. eCollection 2022.
Increasing global diabetes incidence has profound implications for health systems and for people living with diabetes. Guidelines have established clinical targets but there may be variation in clinical outcomes including HbA1c, based on location and practice size. Investigating this variation may help identify factors amenable to systemic improvement interventions. The aims of this study were to identify centre-specific and patient-specific factors associated with variation in HbA1c levels and to determine how these associations contribute to variation in performance across diabetes centres.
This cross-sectional study analysed data for 5,872 people with type 1 (n = 1,729) or type 2 (n = 4,143) diabetes mellitus collected through the Australian National Diabetes Audit (ANDA). A linear mixed-effects model examined centre-level and patient-level factors associated with variation in HbA1c levels.
Mean age was: 43±17 years (type 1), 64±13 (type 2); median disease duration: 18 years (10,29) (type 1), 12 years (6,20) (type 2); female: 52% (type 1), 45% (type 2). For people with type 1 diabetes, volume of patients was associated with increases in HbA1c (p = 0.019). For people with type 2 diabetes, type of centre was associated with reduction in HbA1c (p <0.001), but location and patient volume were not. Associated patient-level factors associated with increases in HbA1c included past hyperglycaemic emergencies (type 1 and type 2, p<0.001) and Aboriginal and Torres Strait Islander status (type 2, p<0.001). Being a non-smoker was associated with reductions in HbA1c (type 1 and type 2, p<0.001).
Centre-level and patient-level factors were associated with variation in HbA1c, but patient-level factors had greater impact. Interventions targeting patient-level factors conducted at a centre level including sick-day management, smoking cessation programs and culturally appropriate diabetes education for and Aboriginal and Torres Strait Islander peoples may be more important for improving glycaemic control than targeting factors related to the Centre itself.
全球糖尿病发病率的上升对卫生系统和糖尿病患者都有深远的影响。指南已经确立了临床目标,但基于地理位置和实践规模的不同,临床结果(包括 HbA1c)可能存在差异。研究这种差异可能有助于确定可以进行系统改进干预的因素。本研究的目的是确定与 HbA1c 水平变化相关的中心特异性和患者特异性因素,并确定这些因素如何导致糖尿病中心之间的表现差异。
本横断面研究分析了通过澳大利亚国家糖尿病审计(ANDA)收集的 5872 名 1 型(n=1729)或 2 型(n=4143)糖尿病患者的数据。线性混合效应模型检查了与 HbA1c 水平变化相关的中心水平和患者水平因素。
平均年龄为:17 岁(1 型),43±17 岁(2 型);中位疾病持续时间:10 岁(1 型),18 岁(2 型);中位数(四分位距)(1 型),29 岁(6,20);女性:52%(1 型),45%(2 型)。对于 1 型糖尿病患者,患者人数与 HbA1c 的增加相关(p=0.019)。对于 2 型糖尿病患者,中心类型与 HbA1c 的降低相关(p<0.001),但地理位置和患者人数则没有。与 HbA1c 升高相关的相关患者水平因素包括过去的高血糖急症(1 型和 2 型,p<0.001)和澳大拉西亚人和托雷斯海峡岛民身份(2 型,p<0.001)。不吸烟与 HbA1c 的降低相关(1 型和 2 型,p<0.001)。
中心水平和患者水平因素与 HbA1c 的变化相关,但患者水平因素的影响更大。在中心层面上针对患者水平因素进行的干预,包括疾病日管理、戒烟计划以及针对澳大拉西亚人和托雷斯海峡岛民的文化适宜的糖尿病教育,可能比针对中心本身的因素更能改善血糖控制。